Business

XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity

Financial Post · September 18, 2026 at 8:07 a.m.

Investigational New Drug application planned for submission to the U.S.

FDA in the fourth quarter of 2026, advancing the Company’s regulatory path toward NDA filing for gout program XRx-026 CALGARY, Alberta, Sept.

18, 20

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity

More from Financial Post

Flame collected in Turin as Changchun prepares to welcome 2027 Winter Universiade

PALESTINIAN REFORM ADVOCATE SAMER SINIJLAWI TELLS THE NEWS FORUM: ‘88% of eligible Palestinian voters have already preregistered for the November 28th election — the first election since 2005’

ModelFront Announces OpenLoc, the Open TMS Built for AI

PRU Quarterly Report Investor Webinar

More in Business

Canada can't launch rockets on its own. A handful of companies want to change that

Flame collected in Turin as Changchun prepares to welcome 2027 Winter Universiade

PALESTINIAN REFORM ADVOCATE SAMER SINIJLAWI TELLS THE NEWS FORUM: ‘88% of eligible Palestinian voters have already preregistered for the November 28th election — the first election since 2005’

ModelFront Announces OpenLoc, the Open TMS Built for AI

PRU Quarterly Report Investor Webinar

EasyPark Receives Three Awards at Canadian Parking Association Conference